“Many of our currently available interventions to prevent the spread of multidrug-resistant organisms (MDROs) and MDRO infections are costly and challenging to implement, which can limit their ...
Expert Rev Anti Infect Ther. 2011;9(8):653-679. As antibiotic options in the treatment of ESBL-producing organisms are extremely limited, carbapenems are the treatment of choice for serious ...